Stockwatch: Bitter-sweet biotech buy-outs
This article was originally published in Scrip
Executive Summary
Speculation that the board of Amylin Pharmaceuticals recently rejected a $3.5 billion unsolicited acquisition offer from Bristol Myers Squibb (BMS) (scripintelligence.com, 29 March 2012) is both logical and fits the profile of one of the many bitter-sweet biotech buy-outs.